Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 3;22:92. doi: 10.1186/s12943-023-01789-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — The immune infiltrate of Braf^V600E/Pten^−/− tumors is altered with loss of Cxcr2. a mMCPCounter analysis performed on bulk RNAseq data from Braf^V600E/Pten^−/−melanoma tumors with or without Cxcr2 predicts significantly enhanced infiltration of T cells, CD8 + T cells, monocytes, NK cells, and lymphatic vessels into Cxcr2^−/− tumors. b FACS analysis of CD45 + myeloid cells in Braf^V600E/Pten^−/− melanoma reveals decreased MDSC-like cells in Cxcr2^−/− tumors. c FACS analysis of CD45 + cells in Braf^V600E/Pten^−/− melanoma tumors identified changes in activated CD4 + CD44 + T cells and CD8 + CD69 + T cells. d Cytokine array for 62 cytokines expressed in TME of Braf^V600E/Pten^−/− tumors revealed one major cytokine, CCL20, that is strongly upregulated with loss of Cxcr2 (n = 4/genotype) based on net density. These data are complemented by increased Ccl20 mRNA with loss of Cxcr2 in Braf^V600E/Pten^−/− tumors. e Cxcl9, Cxcl10, and PD-L1 expression based upon RNAseq analysis from Braf^V600E/Pten^−/− tumors expressing or not expressing Cxcr2 in melanocytes. All statistical significance determined via Welch’s t-test